A new treatment to improve ovarian cancer therapy effectiveness
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
This study is testing a new drug called GRN-300 to see if it can make existing ovarian cancer treatments work better, especially for patients whose cancer hasn't responded well to standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11161652 on NIH RePORTER |
What this research studies
This research investigates the use of a novel drug, GRN-300, which targets a specific protein to enhance the effectiveness of existing ovarian cancer treatments, particularly carboplatin and paclitaxel. The study includes a first-in-human trial to determine the safest dose of GRN-300 when used alone and in combination with weekly paclitaxel. Additionally, it explores how GRN-300 can increase the sensitivity of ovarian cancer cells to another treatment called olaparib, especially in cases where the cancer has developed resistance to standard therapies. By understanding the mechanisms of how GRN-300 works, the research aims to improve treatment outcomes for patients with ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those who have not responded well to standard treatments or have specific genetic mutations.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar approaches, indicating potential for success in enhancing treatment efficacy for ovarian cancer.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Bast, Robert C — University of Tx Md Anderson Can Ctr
- Study coordinator: Bast, Robert C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.